FY26 was a strong year for Resonance Health, and we wanted you to hear it directly from us.

Group revenue rose 42% to $15,751,909, and we returned to profit with a net profit after tax of $1,513,109, a turnaround of more than $3.3 million on last year's loss. Normalised EBITDA came in at $2,550,000, ahead of the $2.0 million we originally guided the market to expect, guidance we upgraded during the year and then beat.

Just as important to us is the quality behind those numbers. We collected a record $14,280,910 in cash receipts, generated positive operating cash flow in every quarter, and finished the year with $4,849,447 in the bank against $2,533,334 of bank debt. This growth was funded from our own operations, not from raising capital.

All three parts of our business, our imaging software, our clinical research organisation and our TrialsWest site network, grew and reinforced each other this year. Our major MASH clinical trial finished patient recruitment, which is a real achievement, but it also means replacing that revenue is now our key near-term priority as we head into FY27. Our $2,533,334 NAB facility matures in March 2027, and the Board is actively working on its renewal well ahead of that date. Our liver fibrosis device remains under development, funded from our own cash flow, with no revenue from it assumed in our near-term plans.

We also strengthened the Board this year, appointing Dr David Fuller and Michael Sistenich, whose drug development and healthcare investment experience will support the decisions ahead of us.

The full Annual Report, including the detailed financial statements, sits alongside this summary. If anything here raises a question for you, we'd genuinely like to hear it through the question box on this page.

FY26 was the year our turnaround showed up in the numbers. Revenue reached $15.8M, up 42% on FY25, and we returned to full-year profit with net profit after tax of $1.5M, a $3.2M swing from last year's loss. Normalised EBITDA rose 83% to $2.6M, lifting our margin from 13% to 16%.

Just as important is the cash behind those numbers. We generated positive operating cashflow in every quarter, with free cashflow of $2.8M, up 148% on FY25. Cash at bank sits at $4.8M and we finished the year with net cash of $2.3M, up from $0.1M a year earlier. ASX has also confirmed we no longer need to lodge quarterly cashflow reports, reflecting that sustained performance.

Each of our three businesses, imaging analysis, clinical trial management and investigator sites, contributed positive profit this year, and all three are backed by contracted work heading into FY27, including $13.8M of trial invoicing still to come and a SaMD pipeline exceeding $12M.

Looking ahead, we've given FY27 guidance of $17M to $22M revenue and $2.6M to $3.6M normalised EBITDA. That guidance is built on existing contracts and pipeline conversion, and deliberately excludes upside from the liver fibrosis device, acquisitions or new sites, so there's more to come if those land. As with all forward-looking guidance, actual results may differ from what we expect.

If you have questions about this result, we'd welcome you raising them through the investor hub.

Resonance Health Limited (ASX: RHT) has released an 'MRI Liver Fibrosis Device Progress & FY26 Portfolio Update' investor presentation. Investors are invited to join a live webinar on June 9th, 2026, to learn more about the company's progress. The webinar will be hosted by the Managing Director & CEO, Andrew Harrison, and Chief Scientific Officer, Dr Wenjie Pang.

The company's dedication to scientific rigour and quality has led to regulatory clearances for a range of Software-as-Medical-Devices (SaMDs) in the USA, Europe, UK, and Australia. Resonance Health's products have gained endorsement from leading physicians worldwide.

The development pipeline includes the MRI Liver Fibrosis Project, aimed at accurately assessing liver fibrosis progression using non-invasive MRI analysis. This presents a significant opportunity in the $40B+ liver diagnostics market.

Resonance Health's profitable platform, combined with the upcoming Liver Fibrosis device launch, positions the company for significant growth. The company's global reach, regulatory moat, and alignment with the GLP-1 trial boom highlight the potential for further expansion.

For further details and to participate in the webinar, please visit our website or contact Andrew Harrison, Managing Director, at andrewh@resonancehealth.com or +61 8 9286 5300. Invest in Resonance Health for a promising future in healthcare technology.

In the latest half-year results, Resonance Health reported a 53% revenue increase, reaching $8.0M, with a normalised EBITDA of $1.6M. The company also achieved a profit after tax of $1.5 million, a significant improvement from the previous year. They are making progress in global pharma trials, expanding their clinic network, and have a substantial pipeline of orders and bids. The new innovative technologies like the "Bridge" tool and non-invasive liver fibrosis device show promise for further growth.

Resonance Health's revenue diversification and rapid scaling across three businesses have been positive, leading to a strong CAGR of ~45% since FY23. The company's strategy focuses on expanding their share of the market by broadening therapeutic areas, offering more services to each customer, and acquiring new customers through organic or acquisitive growth.

Investors can look forward to Resonance Health's continued growth in the global clinical trial market, leveraging their deep expertise in liver and metabolic/obesity areas. The company maintains a strong financial position, disciplined cost control, and aims for responsible growth with a target EBITDA margin range of about 25%. If you have any questions about our latest announcement, feel free to ask.

Resonance Health has seen significant revenue growth and diversification since FY23, with a strong revenue growth of approximately 45% CAGR. The company has expanded its addressable global market, focusing on new imaging endpoints for metabolic and obesity, alongside a growth strategy that aims to increase share of wallet through more therapeutic areas, services, and customers. Growth opportunities include expanding into new therapeutic areas and earlier stage trials, as well as acquisitions in the US and Europe.

The company's FY26 guidance remains at a revenue of $17M and underlying Operating EBITDA of $2M, with plans to grow underlying EBITDA margins to ~12% and target margins of ~25% in the future. Resonance Health prides itself on its deep expertise in liver and related metabolic areas and serves global pharma clients with standardized trial protocols. Investors are encouraged to inquire for further details and clarification on the company's expansion plans and growth opportunities.

Resonance Health Ltd (ASX: RHT) has released an investor strategy day presentation, available for review on our website. The presentation highlights our strong revenue growth, diversified revenue streams, and dedication to scientific rigor, with a focus on providing high-quality quantitative assessments essential in managing diseases and drug development.

Our SaMD products, including FerriScan® and FerriSmart®, are regulatory cleared and internationally recognized for their accuracy in assessing liver iron concentration and fat. We also offer services in medical imaging analysis, clinical trials, and site management operations.

We invite investors to join a live webcast and Q&A session hosted by our leadership team. For further information, contact our Chief Executive Officer Andrew Harrison.

As we move forward, we are focused on expanding into new therapeutic areas, increasing our customer base, and improving operational efficiencies through technology investments. This strategic growth plan positions us for success, with a target EBITDA margin of approximately 25% and a revenue guidance of around $17 million for FY26.

If you have any questions or would like more information, please visit our website or reach out to us directly. We look forward to engaging with our stakeholders and sharing our progress.

Resonance Health

Events

Home

Business Overview

Team

About

Why Invest

Announcements

Market Data

Contact

Shareholder Documents

Shareholder Information

Poppins

Resonance Health Investor Hub

MRI LIVER FIBROSIS DEVICE CLINICAL TRIAL PRELIMINARY RESULTS WEBINAR

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Webinars

Annual reports

Investor presentations